Showing results (131-140 of 229) with videos related to
Sort By:
Pageof 23
Scientific Reports|February 23, 2012
Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapyColleen M O'Connor, Sabina Sheppard, Cassie A Hartline, et al.Leukemia|February 17, 2022
Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALLSujan Piya, Yaling Yang, Seemana Bhattacharya, et al.Blood Advances|March 1, 2024
Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantationWarren B Fingrut, Eric Davis, Anne Archer, et al.Blood Advances|April 12, 2021
Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AMLBrian C Shaffer, Jean-Benoit Le Luduec, Soo Park, et al.Nature Communications|February 17, 2019
Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiationJun Yan, Qingnan Zhao, Konrad Gabrusiewicz, et al.Cancer Research|June 3, 2005
Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomasLynda Song, Andrei Zlobin, Pushpankur Ghoshal, et al.Oncotarget|November 16, 2017
Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemiaRodrigo Jacamo, R Eric Davis, Xiaoyang Ling, et al.Nature Communications|January 27, 2019
FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiationJun Yan, Qingnan Zhao, Konrad Gabrusiewicz, et al.Blood|June 3, 2015
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapyByung-Sik Cho, Zhihong Zeng, Hong Mu, et al.Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialYasuhiro Oki, Michael S Ewer, Daniel J Lenihan, et al.Pageof 23